YAFO Acts as Exclusive Financial Advisor for ImmuneOncia Therapeutics in its Licensing-out Transaction with 3D Medicines

雅法担任ImmuneOncia Therapeutics独家顾问,完成与思路迪医药商业许可交易

Transaction Overview 交易概览

• ImmuneOncia Therapeutics, Inc. signs exclusive license agreement with 3D Medicines, Inc. for the development, manufacture, and commercialization of IMC-002. The agreement includes uses of IMC-002 for oncology indication as a monotherapy or combination agent in the Territory of Greater China.
ImmuneOncia Therapeutics宣布与思路迪医药(3D Medicines Inc.)达成新一代抗CD47单克隆抗体IMC-002肿瘤适应症在大中华区(中国大陆、香港、澳门和台湾)的开发、生产和商业化的独家授权。

• ImmuneOncia to Receive potentially up to $470.5M including $8M Upfront, and Future Development and Commercial Milestone Payments, plus Tiered Royalties on Net Sales
根据协议条款,思路迪医药将支付800万美元的首付款,及未来最高达4.625亿美元的开发和商业里程碑付款,并基于IMC-002在大中华区年度净销售额支付一定比例销售特许使用费。

• Press Release: https://www.prnewswire.com/news-releases/immuneoncia-and-3d-medicines-signed-exclusive-license-agreement-to-develop-manufacture-and-commercialize-imc-002-in-greater-china-301258121.html

YAFO Capital CEO Sean Jiang and Managing Director Fan Zheng attended the signing ceremony and delivered congratulatory speech.
雅法资本CEO蒋晓阳、董事总经理郑帆出席了签约仪式并致贺词

"It has been a great pleasure working with YAFO team. They have been a reliable advisor with strong networks, wonderful communication skills, and full of relevant experiences. YAFO did a great job representing ImmuneOncia in China, and I hope to work with the team again."

-- Jungu Bae, Director of Business Development at ImmuneOncia Therapeutics

ImmuneOncia 业务发展总监Jungu Bae表示:“我们非常荣幸与雅法团队合作。他们是可靠的交易顾问,拥有强大人脉、出色沟通技巧以及丰富经验。雅法作为ImmuneOncia在中国的顾问,工作完成得很出色,我们希望可以与雅法团队再次合作。”

About IMC-002

IMC-002 is a fully human IgG4 monoclonal antibody designed to block the CD47–SIRPα interaction in order to promote the phagocytosis of cancer cells by macrophages. According to its non-clinical results, it binds to human CD47 with an optimal affinity that maximizes efficacy without binding to RBCs or causing anemia which is often seen in other CD47 blocking agents under development. For more information about the Phase 1 clinical trial, visit clinicaltrials.gov, identifier number NCT04306224.

IMC-002是处于全球 I 期临床开发的全人源化IgG4单克隆抗体新药,通过阻断CD47-SIRPα相互作用,促进巨噬细胞对肿瘤细胞的吞噬作用。现有临床前数据表明,IMC-002与人CD47亲和力强,可以最大限度地提高疗效,而不会出现与红细胞结合或引起贫血等其他在研CD47抑制剂常见的副作用。有关IMC-002 I期临床试验(NCT04306224)结果的更多信息,请访问:ClinicalTrials.gov 100 篇论文,并出版了三部著作。该公司获得了 Stanford 大学某知名家族基金的投资。

About ImmuneOncia Therapeutics, Inc.

ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan Corporation in South Korea and Sorrento Therapeutics, Inc. inU.S. ImmuneOncia leverages both companies’ expertise in drug development and antibody engineering. The company’s mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide, and its portfolio includes diverse immune checkpoint antibodies. ImmuneOncia has successfully completed a Phase I study of IMC-001, its leading candidate anti-PDL1 antibody,and a Phase II study was initiated in 2H 2020.For more information, please visit www.immuneoncia.com

ImmuneOncia是一家以肿瘤免疫为核心的生物制药公司。ImmuneOncia是韩国Yuhan公司和美国Sorrento Therapeutics公司于2016年组建的合资公司。ImmuneOncia充分利用了两家公司在药物开发和抗体工程方面的优势,为全球肿瘤患者提供安全、有效的新型免疫疗法,其产品组合包括多种免疫检查点抗体。ImmuneOncia已完成其核心产品PD-L1抗体IMC-001的I期临床研究,并于2020年下半年启动II期临床研究。更多信息,请访问:www.immuneoncia.com

About 3D Medicines inc. 思路迪医药

3D Medicines,Inc. is a biopharmaceutical company at the stage of late clinical development and early commercialization. With the concept “Help people with cancer live longer and better,” aiming for the future long-term survival of tumor patients, 3D Medicines focuses on the development of differentiated next-generation immuno-oncology drugs, to help cancer patients live longer with better quality of life. 3D Medicines has built a pipeline with both innovative biological and small-molecule anti-tumor drugs, and a professional team with global development, registration and commercialization capabilities. For more information, please visit www.3d-medicines.com.

思路迪医药是一家进入商业化阶段的专注肿瘤治疗的医药公司,秉承“帮助肿瘤患者活得更久更好”的理念,针对肿瘤治疗慢病化的未来趋势,为全球肿瘤患者开发差异化的新一代肿瘤免疫治疗药物,延长肿瘤患者的生存时间,改善患者生活品质。公司的产品线包括十余个新一代生物药和小分子抗癌药物,拥有一支具有新药研发、注册和商业化运营能力的国际化团队。更多信息请访问:www.3d-medicines.com

About YAFO Life Science 雅法全球医疗

YAFO Life Science (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and medtech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. For more information regarding YAFO, go to: www.yafocapital.com

雅法全球医疗(YAFO Life Science)是雅法资本旗下的医疗大健康部门,专注于帮助具有“中国角度”的海外医药、医疗器械企业在中国的融资、授权和战略合作;为中国医疗企业提供产品全球授权、海外市场研究服务,寻找海外投资并购标的,及产品商业合作。雅法全球医疗核心合伙人团队均为华尔街资深投行人士或具有跨国药企工作经验;雅法庞大的海外的区域合伙人团队,均具20+年医药行业及交易经验,覆盖美国、日本 、欧洲等主要全球医药创新区域。项目合作请联系:黎琦 | BD Director | 13621979227 | qli@yafocapital.com

Recent Transaction

YAFO Upcoming Events - ACCESS CHINA Forum 2021 -Summer Showcase (June 9-11, 14-18, 2021, Bio Convention Week)

雅法药通中国夏季路演活动将于2021年6月Bio Convention Week期间举行。

Please email Wendi Xiang, wxiang@yafocapital.com, if you want to present or attend our winter partnering event.